Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
AstraZeneca picks Genentech vet Bohen as its next CMO |
|||||||||||||||||||
Two months after Briggs Morrison left the drugmaker for the top job at Syndax Pharmaceuticals, AstraZeneca ($AZN) has announced Sean Bohen will serve as its next Chief Medical Officer. Bohen--formerly the SVP of early development at Genentech--will step into his new role on September 15, at which time he will take responsibility for late-phase development and patient safety at AstraZeneca. Despite the change in R&D focus, Bohen's 12 years at Genentech saw him gain late-phase development experience and skills in some of the areas that AstraZeneca sees as its future, such as targeted cancer therapies and companion diagnostics. Before Genentech, Bohen worked at the Stanford University School of Medicine for nearly a decade. Story | Release
|